Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:44 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2977–3000 of 21,236 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity Disorders Clear all

Conditions: Type II Diabetes, Periodontal Disease
Interventions: Triclosan containing toothpaste, Non-triclosan containing toothpaste; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Graft-Versus-Host Disease
Interventions: Etanercept; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infections, Metabolic Syndrome X
Interventions: Metformin, Placebo, Lifestyle Modification; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Human Immunodeficiency Virus
Interventions: SPARK, HealthMpowerment, PrEP Education; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Giant Cell Arteritis, Granulomatosis With Polyangiitis, Microscopic Polyangiitis, Polyarteritis Nodosa, Takayasu Arteritis
Interventions: Naltrexone Hydrochloride, Placebo Comparator; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 6
States / cities: Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Canakinumab, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 12
States / cities: Anniston, Alabama • Birmingham, Alabama • Peoria, Arizona + 8 more

Conditions: Low Back Pain
Interventions: Spinal Manipulation, Light Massage, Pulsed Ultrasound; Procedure
Lead sponsor: University of Western States; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Allergy;Food, Allergy to Shrimp, Allergy to Cashew Nut (Disorder)
Interventions: Cashew or Shrimp Oral Immunotherapy; Drug
Lead sponsor: Sayantani B. Sindher; Other
Eligibility: 7 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV Infections
Interventions: Vicriviroc; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more

Conditions: Atopic Dermatitis (AD), Non-atopic Healthy Controls
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 17 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Solid Tumor, Adult Lymphoma
Interventions: CYC140; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Duarte, California • Pittsburgh, Pennsylvania • Houston, Texas

Conditions: HIV/AIDS
Interventions: Tele-PrEP Intervention; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: T-Cell Large Granular Lymphocyte Leukemia
Interventions: Oral Azacitidine; Drug
Lead sponsor: Jonathan Brammer; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Columbus, Ohio • Charlottesville, Virginia

Conditions: Lymphoma
Interventions: filgrastim, carboplatin, carmustine, cytarabine, etoposide, ifosfamide, melphalan, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy; Biological · Drug · Procedure + 1 more
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Burns, Knee Injuries, Opioid Use, Pain
Interventions: Opioid Use 90-Days Post Treatment; Behavioral
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 0 Years to 18 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse
Interventions: Ixazomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Omar Nadeem, MD; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV/AIDS
Interventions: WELL Program; Behavioral
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome
Interventions: Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Total-Body Irradiation; Drug · Other · Procedure + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 1 Year to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Primary Immunodeficiency Diseases (PID)
Interventions: SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety), SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety), IV treatment with IGSC, 10%; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 2 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 11
States / cities: Cypress, California • Irvine, California • Los Angeles, California + 8 more

Conditions: Graft-versus-host Disease
Interventions: PRP eye drops, PPP eye drops; Biological
Lead sponsor: Ladan Espandar; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
Interventions: Exogenous Ketone Drink, Placebo; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Asthma
Interventions: FF/GSK573719, FF, FF/VI; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 4
States / cities: St Louis, Missouri • Medford, Oregon • Orangeburg, South Carolina + 1 more

Conditions: HIV/AIDS
Interventions: Intervention Group; Behavioral
Lead sponsor: Michael Ohl; Other
Eligibility: 18 Years to 70 Years
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: HIV Infections
Interventions: INVITE-Home, Clinic-Administered LAI-ART, Oral ART; Other · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Periodontal Treatment Response in Type II Diabetic Patients

The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease

Lifestyle Modification and Metformin Use in the Treatment of HIV

Pre-exposure Prophylaxis Implementation in Central-Eastern European Countries

Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis

Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis

Dose of Spinal Manipulation for Chronic Low Back Pain

Food Allergen OIT for Shrimp and Cashew

Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and Adolescents

Atopic Dermatitis (AD) and Food Allergy

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

Telemedicine for PrEP Throughout Mississippi

Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Older Patients With Refractory or Relapsed Intermediate-Grade Non-Hodgkin's Lymphoma

Opioid Laws and Pediatric Use

Ixazomib + Pomalidomide + Dexamethasone In MM

HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions

Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD

Chronic Exogenous Ketosis in HFpEF

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma

Rural PrEP Delivery

Innovative Administration of Long-Acting Injectables for HIV Treatment Enhancement at Home